{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:12:31Z","timestamp":1789855951760,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T00:00:00Z","timestamp":1411516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-709","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T19:47:56Z","timestamp":1411588076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions"],"prefix":"10.1186","volume":"14","author":[{"given":"Adam","family":"Szulkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"\u00d6tv\u00f6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Olof","family":"Hillerdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytekin","family":"Celep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eviane","family":"Yousef-Fadhel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Skribek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hjerpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Sz\u00e9kely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,24]]},"reference":[{"key":"4896_CR1","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960, 17: 260-271.","journal-title":"Br J Ind Med"},{"issue":"2","key":"4896_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2486\/indhealth.39.183","volume":"39","author":"Y Suzuki","year":"2001","unstructured":"Suzuki Y: Pathology of human malignant mesothelioma\u2013preliminary analysis of 1,517 mesothelioma cases. Ind Health. 2001, 39 (2): 183-185. 10.2486\/indhealth.39.183.","journal-title":"Ind Health"},{"issue":"1","key":"4896_CR3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/JCO.1988.6.1.147","volume":"6","author":"K Antman","year":"1988","unstructured":"Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J: Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women\u2019s Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988, 6 (1): 147-153.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4896_CR4","first-page":"1211","volume":"73","author":"JM Porcel","year":"2006","unstructured":"Porcel JM, Light RW: Diagnostic approach to pleural effusion in adults. Am Fam Physician. 2006, 73 (7): 1211-1220.","journal-title":"Am Fam Physician"},{"issue":"1","key":"4896_CR5","first-page":"19","volume":"17","author":"A Abakay","year":"2013","unstructured":"Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, Kucukoner M, Kaplan MA, Celik Y, Senyigit A: Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci. 2013, 17 (1): 19-24.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"14","key":"4896_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Paoleti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21 (14): 2636-2644. 10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4896_CR7","first-page":"508","volume":"1","author":"AK Nowak","year":"2012","unstructured":"Nowak AK: Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg. 2012, 1 (4): 508-515.","journal-title":"Ann Cardiothorac Surg"},{"issue":"16","key":"4896_CR8","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.ejca.2012.05.018","volume":"48","author":"JK Blayney","year":"2012","unstructured":"Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Fennell DA: Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer. 2012, 48 (16): 2983-2992. 10.1016\/j.ejca.2012.05.018.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4896_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007, 33 (1): 9-23. 10.1016\/j.ctrv.2006.09.006.","journal-title":"Cancer Treat Rev"},{"issue":"36","key":"4896_CR10","doi-asserted-by":"publisher","first-page":"14324","DOI":"10.1073\/pnas.0706803104","volume":"104","author":"J Wang","year":"2007","unstructured":"Wang J, Lohman GJ, Stubbe J: Enhanced subunit interactions with gemcitabine-5\u2032-diphosphate inhibit ribonucleotide reductases. Proc Natl Acad Sci U S A. 2007, 104 (36): 14324-14329. 10.1073\/pnas.0706803104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"4896_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Soria JC: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006, 355 (10): 983-991. 10.1056\/NEJMoa060570.","journal-title":"N Engl J Med"},{"issue":"34","key":"4896_CR12","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1200\/JCO.2009.21.9766","volume":"27","author":"C Reynolds","year":"2009","unstructured":"Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Bepler G: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009, 27 (34): 5808-5815. 10.1200\/JCO.2009.21.9766.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4896_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","volume":"7","author":"ZG Zimling","year":"2012","unstructured":"Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E: Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012, 7 (1): 249-256. 10.1097\/JTO.0b013e318233d6a9.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4896_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cllc.2013.04.013","volume":"14","author":"S Ting","year":"2013","unstructured":"Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW, Christoph DC: ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 2013, 14 (5): 558-567. 10.1016\/j.cllc.2013.04.013. e553","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"4896_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00280-012-1965-0","volume":"70","author":"ZG Zimling","year":"2012","unstructured":"Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E: A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2012, 70 (5): 743-754. 10.1007\/s00280-012-1965-0.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4896_CR16","doi-asserted-by":"publisher","first-page":"e65903","DOI":"10.1371\/journal.pone.0065903","volume":"8","author":"A Szulkin","year":"2013","unstructured":"Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, Hjerpe A, Dobra K: Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One. 2013, 8 (6): e65903-10.1371\/journal.pone.0065903.","journal-title":"PLoS One"},{"issue":"8","key":"4896_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.2012.43.0900","volume":"31","author":"B Besse","year":"2013","unstructured":"Besse B, Olaussen KA, Soria JC: ERCC1 and RRM1: ready for prime time?. J Clin Oncol. 2013, 31 (8): 1050-1060. 10.1200\/JCO.2012.43.0900.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4896_CR18","doi-asserted-by":"publisher","first-page":"e72030","DOI":"10.1371\/journal.pone.0072030","volume":"8","author":"F Mundt","year":"2013","unstructured":"Mundt F, Nilsonne G, Arslan S, Csuros K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A: Hyaluronan and N-ERC\/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One. 2013, 8 (8): e72030-10.1371\/journal.pone.0072030.","journal-title":"PLoS One"},{"issue":"2","key":"4896_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/874212","volume":"35","author":"J Creaney","year":"2013","unstructured":"Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW: Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers. 2013, 35 (2): 119-127.","journal-title":"Dis Markers"},{"issue":"3","key":"4896_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","volume":"82","author":"J Creaney","year":"2013","unstructured":"Creaney J, Dick IM, Segal A, Musk AW, Robinson BW: Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013, 82 (3): 491-498. 10.1016\/j.lungcan.2013.09.016.","journal-title":"Lung Cancer"},{"issue":"5","key":"4896_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U","volume":"92","author":"A Thylen","year":"2001","unstructured":"Thylen A, Hjerpe A, Martensson G: Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001, 92 (5): 1224-1230. 10.1002\/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U.","journal-title":"Cancer"},{"issue":"3","key":"4896_CR22","doi-asserted-by":"publisher","first-page":"37R","DOI":"10.1093\/glycob\/12.3.37R","volume":"12","author":"BP Toole","year":"2002","unstructured":"Toole BP: Hyaluronan promotes the malignant phenotype. Glycobiology. 2002, 12 (3): 37R-42R. 10.1093\/glycob\/12.3.37R.","journal-title":"Glycobiology"},{"issue":"2B","key":"4896_CR23","first-page":"599","volume":"24","author":"Z Liu","year":"2004","unstructured":"Liu Z, Dobra K, Hauzenberger D, Klominek J: Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells. Anticancer Res. 2004, 24 (2B): 599-603.","journal-title":"Anticancer Res"},{"issue":"16","key":"4896_CR24","first-page":"4516","volume":"54","author":"T Asplund","year":"1994","unstructured":"Asplund T, Heldin P: Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 1994, 54 (16): 4516-4523.","journal-title":"Cancer Res"},{"issue":"1","key":"4896_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","volume":"44","author":"R Hassan","year":"2008","unstructured":"Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008, 44 (1): 46-53. 10.1016\/j.ejca.2007.08.028.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4896_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ijc.2910500308","volume":"50","author":"K Chang","year":"1992","unstructured":"Chang K, Pastan I, Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992, 50 (3): 373-381. 10.1002\/ijc.2910500308.","journal-title":"Int J Cancer"},{"issue":"12 Pt 1","key":"4896_CR27","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","volume":"10","author":"R Hassan","year":"2004","unstructured":"Hassan R, Bera T, Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004, 10 (12 Pt 1): 3937-3942.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4896_CR28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/clinchem\/32.6.952","volume":"32","author":"A Hjerpe","year":"1986","unstructured":"Hjerpe A: Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids. Clin Chem. 1986, 32 (6): 952-956.","journal-title":"Clin Chem"},{"issue":"3","key":"4896_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/dc.20202","volume":"32","author":"A Dejmek","year":"2005","unstructured":"Dejmek A, Hjerpe A: The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol. 2005, 32 (3): 160-166. 10.1002\/dc.20202.","journal-title":"Diagn Cytopathol"},{"issue":"1","key":"4896_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.lungcan.2009.05.004","volume":"68","author":"C Flores-Staino","year":"2010","unstructured":"Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer. 2010, 68 (1): 39-43. 10.1016\/j.lungcan.2009.05.004.","journal-title":"Lung Cancer"},{"issue":"1","key":"4896_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/PAT.0b013e32835bc848","volume":"45","author":"A Segal","year":"2013","unstructured":"Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J: A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology. 2013, 45 (1): 44-48. 10.1097\/PAT.0b013e32835bc848.","journal-title":"Pathology"},{"issue":"21","key":"4896_CR32","first-page":"6118","volume":"49","author":"J Klominek","year":"1989","unstructured":"Klominek J, Robert KH, Hjerpe A, Wickstrom B, Gahrton G: Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res. 1989, 49 (21): 6118-6122.","journal-title":"Cancer Res"},{"issue":"2","key":"4896_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ijc.2910510220","volume":"51","author":"D Schmitter","year":"1992","unstructured":"Schmitter D, Lauber B, Fagg B, Stahel RA: Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992, 51 (2): 296-301. 10.1002\/ijc.2910510220.","journal-title":"Int J Cancer"},{"issue":"4","key":"4896_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/carcin\/11.4.673","volume":"11","author":"K Pelin-Enlund","year":"1990","unstructured":"Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, Klockars M, Jantunen K, Gerwin BI, Harris CC, Tuomi T, Vanhala E, Mattson K, Linnainmaa K: Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis. 1990, 11 (4): 673-681. 10.1093\/carcin\/11.4.673.","journal-title":"Carcinogenesis"},{"key":"4896_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2407-11-441","volume":"11","author":"R Otvos","year":"2011","unstructured":"Otvos R, Skribek H, Kis LL, Gloghini A, Markasz L, Flaberg E, Eksborg S, Konya J, Gergely L, Carbone A, Szekely L: Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. BMC Cancer. 2011, 11: 441-10.1186\/1471-2407-11-441.","journal-title":"BMC Cancer"},{"issue":"12","key":"4896_CR36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.exphem.2010.09.001","volume":"38","author":"H Skribek","year":"2010","unstructured":"Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, Masszi T, Kozma A, Adam E, Miseta A, Szekely L: Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol. 2010, 38 (12): 1219-1230. 10.1016\/j.exphem.2010.09.001.","journal-title":"Exp Hematol"},{"key":"4896_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2342-8-13","volume":"8","author":"E Flaberg","year":"2008","unstructured":"Flaberg E, Sabelstrom P, Strandh C, Szekely L: Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging. 2008, 8: 13-10.1186\/1471-2342-8-13.","journal-title":"BMC Med Imaging"},{"issue":"3","key":"4896_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncponc1039","volume":"5","author":"DA Fennell","year":"2008","unstructured":"Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J: Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008, 5 (3): 136-147. 10.1038\/ncponc1039.","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"4896_CR39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1556-0864(15)30366-X","volume":"1","author":"P Ellis","year":"2006","unstructured":"Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol. 2006, 1 (6): 591-601. 10.1097\/01243894-200607000-00017.","journal-title":"J Thorac Oncol"},{"issue":"2\u20133","key":"4896_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11864-008-0071-3","volume":"9","author":"HL Kindler","year":"2008","unstructured":"Kindler HL: Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008, 9 (2\u20133): 171-179.","journal-title":"Curr Treat Options Oncol"},{"key":"4896_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1756-9966-28-92","volume":"28","author":"G Nilsonne","year":"2009","unstructured":"Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlof AK, Fernandes AP, Bjornstedt M, Dobra K: Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res. 2009, 28: 92-10.1186\/1756-9966-28-92.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"4896_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/annonc\/mds335","volume":"24","author":"AC Vilmar","year":"2013","unstructured":"Vilmar AC, Santoni-Rugiu E, Sorensen JB: Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol. 2013, 24 (2): 309-314. 10.1093\/annonc\/mds335.","journal-title":"Ann Oncol"},{"issue":"9","key":"4896_CR43","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","volume":"24","author":"GL Ceresoli","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Santoro A: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006, 24 (9): 1443-1448. 10.1200\/JCO.2005.04.3190.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4896_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","volume":"11","author":"N Katirtzoglou","year":"2010","unstructured":"Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN: Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010, 11 (1): 30-35. 10.3816\/CLC.2010.n.005.","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"4896_CR45","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/JTO.0b013e31818b174d","volume":"3","author":"G Hillerdal","year":"2008","unstructured":"Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A: Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol. 2008, 3 (11): 1325-1331. 10.1097\/JTO.0b013e31818b174d.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-709\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T05:58:51Z","timestamp":1630562331000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,24]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4896"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-709","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,24]]},"assertion":[{"value":"16 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"709"}}